Clinical trials: Malignant Melanoma
Neuroblastoma, Rhabdomyosarcoma
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor
- Trial name
- NCT01962103
- Testing
- nab-paclitaxel
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Pancreatic Cancer, BRAF Mutant Colorectal Cancer
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite…
- Conditions
- Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer
- Trial name
- NCT01351103
- Testing
- LGK974, PDR001
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Nevus, Racial Melanosis
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
This study aims to validate the use of laser in vivo confocal microscopy as an early diagnostic and differentiation tool of pigmented conjunctival lesions, evaluate the efficacy of in vivo confocal microscopy for follow-up (as a…
- Conditions
- Nevus, Racial Melanosis, Primary Acquired Melanosis, Conjunctival Malignant Melanoma
- Trial name
- NCT01993654
- Testing
- HRT III with Non-Contact Cornea Rostock Module
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Metastatic Melanoma, Unresectable Melanoma
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
This is one phase III, randomized, open-label study in comparison of JS001 with dacarbazine as the 1st-line therapy for adult (≥18 years) subjects with unresectable or metastatic melanoma.
- Trial name
- JS001 (NCT03430297)
- Testing
- JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W
- Where
- 11 sites in China
- Volunteers
- 256 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
The goal of this study is to determine a safe dose of GR-MD-02 used in combination with the FDA-approved dose of ipilimumab (3 mg/kg) in patients who have advanced melanoma. GR-MD-02 is a galectin.
- Trial name
- NCT02117362
- Testing
- 1 mg/kg GR-MD-02, 2 mg/kg GR-MD-02, 4 mg/kg GR-MD-02
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Providence Health & Services
Melanoma, Acral Melanoma
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.
- Conditions
- Melanoma, Acral Melanoma, Temozolomide, Apatinib
- Trial name
- NCT05512481
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Solid Tumor
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
The purpose of this study is to determine whether TBI-1401(HF10), a spontaneously attenuated mutant of Herpes Simplex Virus Type 1 (HSV-1), is safe and tolerable in the treatment of solid tumors with superficial lesions.
- Trial name
- NCT02428036
- Testing
- TBI-1401(HF10)
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Takara Bio Inc.
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable…
- Trial name
- NCT02211131
- Testing
- Talimogene Laherparepvec, Immediate surgical resection of melanoma lesion(s)
- Where
- 46 sites in United States, Australia and 7 more
- Volunteers
- 150 people
- Sponsor
- Amgen
Urinary Bladder Cancer, Bladder Tumors
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer.
- Conditions
- Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder, Malignant Melanoma
- Trial name
- NCT02897765
- Testing
- NEO-PV-01, Nivolumab, Adjuvant
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- BioNTech US Inc.
Melanoma
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
The purpose of this study is to find out what effects, good and/or bad, vemurafenib has on the patient and the melanoma. Specifically, the investigators want to know how well vemurafenib shrinks melanoma.
- Trial name
- NCT01474551
- Testing
- vemurafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
IFx-Hu2.0 Expanded Access Program
Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or…
- Conditions
- Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT04853602
- Testing
- IFx-Hu2.0
- Sponsor
- TuHURA Biosciences, Inc.
Melanoma
Study of PI-88 in Patients With Advanced Melanoma
The purpose of this study is to determine whether PI-88 is safe and effective in the treatment of advanced melanoma.
- Trial name
- NCT00068172
- Testing
- PI-88
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Cellxpert Biotechnology Corp.
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy
Prior preclinical and clinical studies have shown that tumors from patients with advanced melanoma contain tumor-infiltrating lymphocytes (TIL) with anti-tumor reactivity.
- Trial name
- NCT00604136
- Testing
- tumor infiltrating lymphocytes
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Carcinoma, Non-Small-Cell Lung, Melanoma
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03891953
- Testing
- DKY709, PDR001
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Cutaneous Squamous Cell Carcinoma
Personalised Immunotherapy Platform
This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours.
- Conditions
- Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- PIP-PREDICT (NCT06536257)
- Testing
- Predictive model
- Where
- 3 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- Melanoma Institute Australia
Skin Carcinoma
A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer
This clinical trial studies whether a disposable negative pressure wound therapy (dNPWT) device, SNaP Wound Care System (Ultraportable Mechanically Powered Negative Pressure Wound Therapy) (SNaP), promotes wound healing in the…
- Trial name
- NCT07032701
- Testing
- Best Practice, Educational Intervention, Electronic Health Record Review
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer, Gynecologic Cancer
Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy
This trial offers support and assistance to patients wishing to quit smoking in order to increase the success rate of smoking cessation and all the benefits associated with it.
- Conditions
- Breast Cancer, Gynecologic Cancer, Digestive Cancer, Melanoma
- Trial name
- RESPIRE (NCT04899492)
- Testing
- Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT), Hypnotherapy
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Institut Cancerologie de l'Ouest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.